Recombinant factor IX

GC White II, A Beebe, B Nielsen - Thrombosis and haemostasis, 1997 - thieme-connect.com
Departments of Medicine and Pharmacology, Center for Thrombosis and Hemostasis,
Comprehensive Hemophilia Diagnosis and Treatment Genler, University of North Carolina,
Chapel Hill, NC, USA lntroduction tion of ttre nascent factor IX polypeptide to the lumen of
the endoplasmic reticulum, the signal sequence is removed. N-linked glycans, two in the
activation domain, and O-linked glycans, two in the EGF domain and three in the activation
peptide, are affached and processed to branched-chain s [uc-tures (1). Twelve glutamic acid …

Clinical evaluation of recombinant factor IX.

G White, A Shapiro, M Ragni, P Garzone… - Seminars in …, 1998 - europepmc.org
The pharmacokinetics, safety, and efficacy of recombinant factor IX (rFIX) have been
evaluated in previously treated and untreated patients with hemophilia B. In a study of 56
previously treated patients, there was a total of 1,070 hemorrhages, which required 1,514
infusions of rFIX. Of the 1,070 episodes, 80% resolved after a single rFIX infusion. The
majority of the remaining episodes requiring more than 1 infusion were either major or
complicated hemorrhages. Eighty-seven percent of the 1,514 infusions were rated by the …